Results 141 to 150 of about 204,163 (273)
Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia
American Journal of Hematology, Volume 101, Issue 5, Page 1019-1024, May 2026.ABSTRACT Preclinical studies showed a synergistic antileukemia activity with combination of selective XPO1 inhibitor selinexor (SEL) and venetoclax (VEN), with potential to overcome VEN resistance by reducing the anti‐apoptotic protein MCL1. In an investigator‐sponsored, open‐label, phase Ib study (NCT03955783), adult patients with relapsed or ...
Somedeb Ball +11 more
wiley +1 more source
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT Background This study evaluated the efficacy and safety of mecapegfilgrastim for preventing immunochemotherapy‐induced neutropenia in treatment‐naive patients with diffuse large B‐cell lymphoma (DLBCL). Methods In this open‐label, multicenter exploratory trial, patients were randomized in a 2:1 ratio to receive mecapegfilgrastim or no ...
Jie Wang +15 more
wiley +1 more source
Febrile Neutropenia in Intensive Care Unit
Southwest Respiratory and Critical Care Chronicles, 2015 Febrile neutropenia is a serious complication of cancer treatment and causes significant morbidity and mortality, especially when these patients present with sepsis or septic shock requiring intensive care unit admission.
Nattamol Hosiriluck, Saba Radhi
doaj
Hematology, Transfusion and Cell TherapyFebrile neutropenia is a major complication of the treatment of patients with hematologic diseases. Recent epidemiologic changes, with an increase in infection caused by drug-resistant bacteria, represent a major challenge for the proper management of ...
Marcio Nucci +9 more
doaj +1 more source
Influence of Febrile Neutropenia Period on Plasma Viscosity at Malignancy
The Scientific World Journal, 2013 Cancer, chemotherapy, and infections all together make changes in blood rheology and may affect the defense mechanisms by changing the thrombocyte function and endothelial cell.
Ibrahim Tek +4 more
doaj +1 more source
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. [PDF]
, 2019 BackgroundPALOMA-2 confirmed that first-line palbociclib + letrozole improved progression-free survival (hazard ratio, 0.58; 95% confidence interval, 0.46-0.72) in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor ...
Diéras, Véronique +11 more
core
Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.• XPO1 hyperactivation promotes leukaemogenesis by altering nucleocytoplasmic transport and transcriptional control in acute myeloid leukaemia (AML). • Selinexor and eltanexor show preferential activity in NPM1‐mutated, DEK::NUP214‐positive and SF3B1‐mutated myeloid neoplasms.
Yifan Liu +4 more
wiley +1 more source
The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review
Health Science Reports, Volume 9, Issue 5, May 2026.ABSTRACT Background and Aims The integration of biosimilars into pediatric healthcare represents a significant evolution in treatment accessibility and cost‐effectiveness. Biosimilars—biological products highly similar to already approved biologics, have emerged as promising alternatives for managing chronic and rare pediatric conditions, including ...
Zubaier Ahmed +6 more
wiley +1 more source
International Journal of Cancer, Volume 158, Issue 9, Page 2219-2228, 1 May 2026.What's new? Anti‐angiogenic drugs have shown promising efficacy as a second‐line treatment for advanced gastric cancer. However, it remains unclear how alterations in the tumor microenvironment following first‐line immunotherapy may impact tumor angiogenesis and influence subsequent therapeutic outcomes. This single‐arm study prospectively explored the
Xiaoting Ma +11 more
wiley +1 more source
Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications
MedComm, Volume 7, Issue 5, May 2026.Mutant isocitrate dehydrogenase affects multiple cancer types. Alterations in IDH1 and IDH2 result in abnormal enzyme activity, leading to the overproduction of D‐2‐hydroxyglutarate (D‐2HG). This metabolite disrupts cellular metabolism and epigenetic regulation, driving cancer initiation, progression, and metastasis.
Yuhan Fang +6 more
wiley +1 more source